Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment
Rodman & Renshaw Global Investment Conference 2013
CAMBRIDGE, Mass. -- September 3, 2013
Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that Zalicus management will present at the Rodman & Renshaw
15^th Annual Global Investment Conference at 10:25 a.m. ET on Monday,
September 9, 2013 in New York. Interested parties may access a live webcast of
the presentation by visiting the Zalicus website at www.zalicus.com. The
webcast will be archived on the Zalicus website following the event.
Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates, their potential and the plans for their clinical and
preclinical development, the Zalicus selective Ion channel modulation
technology and related preclinical product candidates and its other business
plans. These forward-looking statements about future expectations, plans,
objectives and prospects of Zalicus and its product candidates may be
identified by words like "believe," "expect," "may," "will," "should," "seek,"
“plan” or “could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the development and
regulatory approval of Zalicus’ product candidates, including risks relating
to formulation and clinical development of Z160 and Z944, the unproven nature
of the Zalicus drug discovery technologies, the Company's ability to obtain
additional financing or funding for its research and development, and those
other risks that can be found in the "Risk Factors" section of Zalicus' annual
report on Form 10-K on file with the Securities and Exchange Commission and
the other reports that Zalicus periodically files with the Securities and
Exchange Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.
(c) 2013 Zalicus Inc. All rights reserved.
Justin Renz, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.